Semaglutide and tirzepatide dosage: why only a prescriber can set it

Semaglutide and tirzepatide are prescription medicines, so this page lists the FDA-approved products and links each official label instead of stating any dose.

Basics6 min read

Key takeaway

Semaglutide and tirzepatide are prescription medicines. The FDA-approved semaglutide products are Ozempic, Rybelsus and Wegovy from Novo Nordisk, first approved in 2017. The tirzepatide products are Mounjaro and Zepbound from Eli Lilly, first approved in 2022. A licensed prescriber sets the dose from the FDA label, which we link instead of quoting. FDA has reported dosing errors with compounded versions and has warned against research-labeled products sold for human use.

At a glance

Article typeBasics
Main guideWhat is semaglutide? Structure, research and FDA status
Regulatory statusFDA-approved“It is an FDA-approved prescription drug (Ozempic, Wegovy, Rybelsus)” (Where to buy semaglutide)
ClassMetabolic & weight
Body systemsEndocrine & metabolism
Studies cited0 in this article · 29 across 14 articles on Semaglutide
ProductSemaglutide product page

Most people who search semaglutide dosage or tirzepatide dosage want a number. This page does not give one, on purpose. Semaglutide and tirzepatide are prescription medicines, and a licensed prescriber sets each person's dose using the FDA-approved label. Below you will find the approved products, a link to each official label, and what FDA has said about dosing problems with compounded and research products. Sources were checked on November 17, 2026.

Quick answer: There is no single semaglutide or tirzepatide dosage to look up. Each FDA-approved product has its own label, and a licensed prescriber decides what applies to you. This page links those labels and does not restate any dose. Research-grade semaglutide and tirzepatide are laboratory reagents for laboratory research use only, not for human or veterinary use, and they are never a source of dosing information.

Why doesn't this page list a dose?

On Drugs@FDA, the marketed versions of every product in Table 1 carry the marketing status "Prescription" (Drugs@FDA). The products differ in form and in approved uses, and each has its own label with a dosage section written for prescribers. A dose copied from one label, or from a web page, can be wrong for a different product or a different person.

FDA's records show what goes wrong when people work out doses outside that system. Its reports of dosing errors with compounded products are covered below. We supply laboratory reagents, and we do not give dosing, preparation or administration information for any compound.

Which semaglutide and tirzepatide products are FDA-approved?

Table 1 lists the FDA-approved products, their makers, when FDA first approved them and the uses on their current labels. The approval dates come from Drugs@FDA. The uses come from each label on DailyMed, the National Library of Medicine's label database. Labels change, so check the revision date on the label itself.

Table 1

FDA-approved semaglutide and tirzepatide products (labels checked November 17, 2026)

Product Maker Ingredient and form First FDA approval Approved uses on the current label Official label
Ozempic (injection) Novo Nordisk Semaglutide, injection December 2017 Adults with type 2 diabetes: to improve blood sugar control with diet and exercise; to reduce the risk of major cardiovascular events in those with established cardiovascular disease; to reduce the risk of sustained decline in kidney function, end-stage kidney disease and cardiovascular death in those with chronic kidney disease DailyMed
Rybelsus and Ozempic tablets Novo Nordisk Semaglutide, tablets September 2019 (Rybelsus); Ozempic tablets name approved January 2026 Adults with type 2 diabetes: to improve blood sugar control with diet and exercise; to reduce the risk of major cardiovascular events in those at high risk DailyMed
Wegovy (injection and tablets) Novo Nordisk Semaglutide, injection and tablets June 2021 (injection); December 2025 (tablets) With a reduced-calorie diet and more physical activity: to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight; to reduce excess body weight and maintain the reduction long term in adults with obesity, or overweight with a weight-related condition (the injection also covers patients 12 and older with obesity). The injection is also approved, under accelerated approval, for noncirrhotic MASH with moderate to advanced liver fibrosis in adults DailyMed
Mounjaro Eli Lilly Tirzepatide, injection May 2022 To improve blood sugar control with diet and exercise in adults and children 10 and older with type 2 diabetes; to reduce the risk of major cardiovascular events in adults with type 2 diabetes at high risk DailyMed
Zepbound Eli Lilly Tirzepatide, injection November 2023 With a reduced-calorie diet and more physical activity: to reduce excess body weight and maintain the reduction long term in adults with obesity, or overweight with a weight-related condition; to treat moderate to severe obstructive sleep apnea in adults with obesity DailyMed

Approval histories are on Drugs@FDA: Ozempic injection, Rybelsus and Ozempic tablets, Wegovy injection, Wegovy tablets, Mounjaro and Zepbound. For how the two molecules differ in research, see our tirzepatide and semaglutide comparison.

What does the official label contain?

Each label on DailyMed is the full prescribing information FDA approved for that product. It includes a dosage and administration section for prescribers, warnings, and a Medication Guide written for patients. FDA explains that a Medication Guide is patient labeling that is part of the approved prescription drug labeling and must be given to patients when the product is dispensed (FDA).

Reading a label is not the same as having a dose chosen for you. The prescriber weighs the specific product, the approved use, and your health history and other medicines. Questions about a dose belong with that prescriber or your pharmacist.

Why do compounded products carry dosing-error risk?

Compounded semaglutide and tirzepatide are not FDA-approved, so FDA has not reviewed them for safety, effectiveness or quality before they are sold. FDA has described specific dosing problems with them:

  • Measuring errors. In July 2024, FDA reported adverse events tied to dosing errors with compounded semaglutide injections. Patients measured the wrong amount from multiple-dose vials, and in some cases clinicians miscalculated doses. FDA also noted that compounded products come in varying concentrations. Some patients were hospitalized (FDA alert).
  • Doses beyond the label. FDA has received reports involving doses beyond the FDA-approved label for compounded semaglutide and tirzepatide (FDA).
  • Report counts. As of May 31, 2026, FDA had received 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide, and says such events are likely underreported.

FDA tells health care providers to "be vigilant when prescribing compounded semaglutide or tirzepatide products." Since the drug shortages ended, compounding of both has also been sharply limited; see our guides to compounded semaglutide and compounded tirzepatide.

Why aren't research products a source of dosing information?

Research-grade semaglutide and tirzepatide are laboratory reagents, sold for laboratory research use only, not for human or veterinary use. They have no FDA-approved label, no prescriber and no human dosing information, and they are not an alternative to a prescription medicine.

FDA has warned companies that sold semaglutide, tirzepatide and similar products falsely labeled for research purposes while selling them "directly to consumers for human use with dosing instructions." FDA urges consumers not to buy them, describing them as "of unknown quality" and saying they "may be harmful." In a February 2025 warning letter, FDA said a seller's semaglutide and tirzepatide products were drugs intended for human use despite "research use only" statements. See what research use only means.

Where should you go for a dose?

  • A licensed prescriber. A physician, nurse practitioner or physician assistant who can review your health history decides whether one of these medicines fits and at what dose.
  • A licensed pharmacy. If you buy online, FDA's BeSafeRx program explains how to buy prescription medicines online safely.
  • The label. Use the DailyMed links in Table 1 to read the current label and Medication Guide.
  • Problems. Report side effects or medication errors to FDA through MedWatch.

Frequently asked questions about semaglutide and tirzepatide dosage

What is the semaglutide dosage?

We do not state doses. Your prescriber sets the dose using the FDA-approved label for the specific product. The labels are linked in Table 1.

What is the tirzepatide dosage?

The same applies. Mounjaro and Zepbound each have an FDA label, and a licensed prescriber decides the dose.

Is compounded semaglutide dosed the same way as the brand products?

Not necessarily. FDA notes that compounded products come in varying concentrations and has received reports of dosing errors. Follow your prescriber and pharmacist.

Can research-grade semaglutide or tirzepatide be used instead?

No. Research-grade material is a laboratory reagent, not for human or veterinary use, and not a substitute for a prescription medicine.

What to know now

  • Prescription only: every approved semaglutide and tirzepatide product is listed by FDA as prescription.
  • Approved products: Ozempic, Rybelsus and Wegovy (Novo Nordisk); Mounjaro and Zepbound (Eli Lilly).
  • Dose: set by a licensed prescriber from the FDA label; read the label on DailyMed.
  • Compounded: not FDA-approved; FDA has reported dosing errors and adverse events.
  • Research grade: laboratory reagents, not for human or veterinary use, with no human dosing information.

What we're watching

New approved uses and label revisions for these products, which change what the labels cover, and further FDA action on compounded and research-labeled GLP-1 products.

Also in the library

More for endocrine & metabolism

All 38 compounds for endocrine & metabolism

Sources: National Library of Medicine. DailyMed: Ozempic (semaglutide) injection, DailyMed: Ozempic (semaglutide) injection, Novo Nordisk; National Library of Medicine. DailyMed: Rybelsus and Ozempic (semaglutide) tablets, DailyMed: Rybelsus and Ozempic (semaglutide) tablets, Novo Nordisk; National Library of Medicine. DailyMed: Wegovy (semaglutide) injection and tablets, DailyMed: Wegovy (semaglutide) injection and tablets, Novo Nordisk; National Library of Medicine. DailyMed: Mounjaro (tirzepatide) injection, DailyMed: Mounjaro (tirzepatide) injection, Eli Lilly and Company; National Library of Medicine. DailyMed: Zepbound (tirzepatide) injection, DailyMed: Zepbound (tirzepatide) injection, Eli Lilly and Company; U.S. Food and Drug Administration. Drugs@FDA: NDA 209637 (Ozempic) . https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637, Drugs@FDA: NDA 209637 (Ozempic); U.S. Food and Drug Administration. Drugs@FDA: NDA 213051 (Rybelsus and Ozempic tablets) . https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213051, Drugs@FDA: NDA 213051 (Rybelsus and Ozempic tablets); U.S. Food and Drug Administration 2026; U.S. Food and Drug Administration. Drugs@FDA: NDA 215256 (Wegovy injection) . https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256, Drugs@FDA: NDA 215256 (Wegovy injection); U.S. Food and Drug Administration. Drugs@FDA: NDA 218316 (Wegovy tablets) . https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218316, Drugs@FDA: NDA 218316 (Wegovy tablets); U.S. Food and Drug Administration. Drugs@FDA: NDA 215866 (Mounjaro) . https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866, Drugs@FDA: NDA 215866 (Mounjaro); U.S. Food and Drug Administration. Drugs@FDA: NDA 217806 (Zepbound) . https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806, Drugs@FDA: NDA 217806 (Zepbound); U.S. Food and Drug Administration. Medication guides . https://www.fda.gov/drugs/drug-safety-and-availability/medication-guides, Medication guides; U.S. Food and Drug Administration 2024; U.S. Food and Drug Administration 2026, FDA's concerns with unapproved GLP-1 drugs used for weight loss; U.S. Food and Drug Administration 2025, Warning letter: USApeptide.com, MARCS-CMS 696885; U.S. Food and Drug Administration. BeSafeRx: Your source for online pharmacy information . https://www.fda.gov/drugs/buying-using-medicine-safely/besaferx-your-source-online-pharmacy-information, BeSafeRx: Your source for online pharmacy information; U.S. Food and Drug Administration. MedWatch: The FDA safety information and adverse event reporting program . https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program, MedWatch: The FDA safety information and adverse event reporting program. All 18 citations

Back to the research library

References

  1. National Library of Medicine. DailyMed: Ozempic (semaglutide) injection, Novo Nordisk. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
  2. National Library of Medicine. DailyMed: Rybelsus and Ozempic (semaglutide) tablets, Novo Nordisk. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
  3. National Library of Medicine. DailyMed: Wegovy (semaglutide) injection and tablets, Novo Nordisk. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  4. National Library of Medicine. DailyMed: Mounjaro (tirzepatide) injection, Eli Lilly and Company. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
  5. National Library of Medicine. DailyMed: Zepbound (tirzepatide) injection, Eli Lilly and Company. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  6. U.S. Food and Drug Administration. Drugs@FDA: NDA 209637 (Ozempic). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637
  7. U.S. Food and Drug Administration. Drugs@FDA: NDA 213051 (Rybelsus and Ozempic tablets). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213051
  8. U.S. Food and Drug Administration. (2026, January 30). Supplement approval letter, NDA 213051/S-030 (name change from Rybelsus, formulation R2, to Ozempic tablets). https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/213051Orig1s030ltr.pdf
  9. U.S. Food and Drug Administration. Drugs@FDA: NDA 215256 (Wegovy injection). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256
  10. U.S. Food and Drug Administration. Drugs@FDA: NDA 218316 (Wegovy tablets). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218316
  11. U.S. Food and Drug Administration. Drugs@FDA: NDA 215866 (Mounjaro). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866
  12. U.S. Food and Drug Administration. Drugs@FDA: NDA 217806 (Zepbound). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806
  13. U.S. Food and Drug Administration. Medication guides. https://www.fda.gov/drugs/drug-safety-and-availability/medication-guides
  14. U.S. Food and Drug Administration. (2024). FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
  15. U.S. Food and Drug Administration. (2026). FDA's concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026). https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  16. U.S. Food and Drug Administration. (2025, February 26). Warning letter: USApeptide.com, MARCS-CMS 696885. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/usapeptidecom-696885-02262025
  17. U.S. Food and Drug Administration. BeSafeRx: Your source for online pharmacy information. https://www.fda.gov/drugs/buying-using-medicine-safely/besaferx-your-source-online-pharmacy-information
  18. U.S. Food and Drug Administration. MedWatch: The FDA safety information and adverse event reporting program. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program